» Articles » PMID: 23682212

A Longitudinal Study of Risk Factors for Community-based Home Help Services in Alzheimer's Disease: the Influence of Cholinesterase Inhibitor Therapy

Overview
Publisher Dove Medical Press
Specialty Geriatrics
Date 2013 May 18
PMID 23682212
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To investigate the long-term effects of cholinesterase inhibitor (ChEI) therapy and the influence of sociodemographic and clinical factors on the use of community-based home help services (HHS) by patients with Alzheimer's disease (AD).

Methods: This 3-year, prospective, multicenter study included 880 AD patients treated with donepezil, rivastigmine, or galantamine in a routine clinical setting. At baseline and every 6 months, the patients were assessed with several rating scales, including the Mini-Mental State Examination, Instrumental Activities of Daily Living (IADL), and Physical Self-Maintenance Scale. Doses of ChEI and amounts of HHS per week were recorded. Cox regression models were used to predict the time to HHS, and multiple linear regression was used to predict the volume of HHS used.

Results: During the study, 332 patients (38%) used HHS. Factors that both postponed HHS use and predicted lower amounts of HHS were higher doses of ChEIs, better IADL ability, and living with family. Men, younger individuals, and those with a slower IADL decline showed a longer time to HHS, whereas female sex, a lower cognitive status, or more medications at baseline predicted fewer hours of HHS.

Conclusions: Higher doses of ChEI might reduce the use of HHS, possibly reducing the costs of community-based care. Female spouses provide more informal care than do male spouses, so the likelihood of using HHS is greater among women with AD. The "silent group" of more cognitively impaired and frail elderly AD patients receives less HHS, which might precipitate institutionalization.

Citing Articles

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.

Wattmo C, Blennow K, Hansson O BMC Neurol. 2020; 20(1):10.

PMID: 31918679 PMC: 6951013. DOI: 10.1186/s12883-019-1591-0.


Computer-Aided Multi-Target Management of Emergent Alzheimer's Disease.

Kim H, Han H Bioinformation. 2018; 14(4):167-180.

PMID: 29983487 PMC: 6016757. DOI: 10.6026/97320630014167.


Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease: a prospective, observational study of factors affecting survival time from admission to death.

Wattmo C, Londos E, Minthon L BMC Neurol. 2016; 16(1):156.

PMID: 27581368 PMC: 5007849. DOI: 10.1186/s12883-016-0675-3.


Real-world evaluation of compliance and preference in Alzheimer's disease treatment.

Pai M, Aref H, Bassil N, Kandiah N, Lee J, Srinivasan A Clin Interv Aging. 2015; 10:1779-87.

PMID: 26622172 PMC: 4639476. DOI: 10.2147/CIA.S85319.


Lifetime expectancy and quality-adjusted life-year in Alzheimer's disease with and without cerebrovascular disease: effects of nursing home replacement and donepezil administration--a retrospective analysis in the Tajiri Project.

Meguro K, Akanuma K, Meguro M, Kasai M, Ishii H, Yamaguchi S BMC Neurol. 2015; 15:227.

PMID: 26542372 PMC: 4635582. DOI: 10.1186/s12883-015-0475-1.


References
1.
Hawranik P . The role of cognitive status in the use of inhome services: implications for nursing assessment. Can J Nurs Res. 1998; 30(2):45-65. View

2.
Lopez O, Becker J, Wisniewski S, Saxton J, Kaufer D, DeKosky S . Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002; 72(3):310-4. PMC: 1737770. DOI: 10.1136/jnnp.72.3.310. View

3.
Doty P, Jackson M, Crown W . The impact of female caregivers' employment status on patterns of formal and informal eldercare. Gerontologist. 1998; 38(3):331-41. DOI: 10.1093/geront/38.3.331. View

4.
Lawton M, Brody E . Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969; 9(3):179-86. View

5.
Birks J . Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006; (1):CD005593. PMC: 9006343. DOI: 10.1002/14651858.CD005593. View